← All Dermata Therapeutics, INC filings

Dermata Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
DRMA
Dermata Therapeutics, INC
10-K: Dermata Therapeutics Pivots to DTC Skincare Amid Losses
Dermata Therapeutics shifts focus from prescription drugs to direct-to-consumer and B2B skincare products, reporting continued losses and a going concern warning.
NASDAQ
DRMA
Dermata Therapeutics, INC
10-K: Dermata Therapeutics Files 10-K, Provides Update on Clinical Programs and Financial Position
Dermata Therapeutics reports its 2024 financial results and provides an update on the clinical development of its lead product candidates, XYNGARI and DMT410, including the ongoing Phase 3 trial for acne and a collaboration with Revance for hyperhidrosis.
NASDAQ
DRMA
Dermata Therapeutics, INC
10-K: Dermata Therapeutics Outlines Securities and Financial Structure in 10-K Filing
Dermata Therapeutics' 10-K filing details its capital structure, including common and preferred stock, warrants, and anti-takeover provisions, alongside its financial performance and clinical development pipeline.